0, 0% af patienterne i Keppragruppen og 1, 0% patienterne i placebogruppen oplevede alvorlige bivirkninger.
Serious undesirable effects were experienced in 0.0% of the patients in the Keppra group and 1.0% of the patients in the placebo group.